Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma

被引:130
作者
Sampson, John H. [1 ,3 ]
Archer, Gary E. [1 ,2 ]
Mitchell, Duane A. [1 ,2 ]
Heimberger, Amy B. [2 ,4 ]
Bibner, Darell D. [2 ,3 ]
机构
[1] Duke Univ, Med Ctr, Dept Surg, Div Neurosurg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Antigens; Central nervous system neoplasms; Epidermal growth factor receptor; Immunotherapy;
D O I
10.1016/j.smim.2008.04.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Conventional therapies for malignant gliomas (MGs) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by non-specific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise eradication of neoplastic cells. The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in MGs and other neoplasms. This mutation encodes a constitutively active tyrosine kinase that enhances tumorgenicity and migration and confers radiation and chemotherapeutic resistance. This in-frame deletion mutation splits a codon resulting in the creation of a novel glycine at the fusion junction between normally distant parts of the molecule and producing a sequence re-arrangement which creates a tumor-specific epitope for cellular or humoral immunotherapy in patients with MGs. We have previously shown that vaccination with a peptide that spans the EGFRvIII fusion junction is an efficacious irrimunotherapy in syngeneic murine models, but patients with MGs have a profound immunosuppression that may inhibit the ability of antigen presenting cells (APCs), even those generated ex vivo, to induce EGFRvlll-specific immune responses. In this report, we summarize our results in humans targeting this mutation in two consecutive and one multi-institutional Phase II immunotherapy trials. These trials demonstrated that vaccines targeting EGFRvIII are capable of inducing potent T- and B-cell immunity in these patients, and lead to an unexpectedly long survival time. Most importantly, vaccines targeting EGFRvIII were universally successful at eliminating tumor cells expressing the targeted antigen without any evidence of symptomatic collateral toxicity. These studies establish the tumor-specific EGFRvIII mutation as a novel target for humoral- and cell-mediated immunotherapy in a variety of cancers. The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:267 / 275
页数:9
相关论文
共 189 条
[81]   Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance [J].
Lammering, G ;
Valerie, K ;
Lin, PS ;
Hewit, TH ;
Schmidt-Ullrich, RK .
RADIOTHERAPY AND ONCOLOGY, 2004, 72 (03) :267-273
[82]   Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity [J].
Lammering, G ;
Hewit, TH ;
Holmes, M ;
Valerie, K ;
Hawkins, W ;
Lin, PS ;
Mikkelsen, RB ;
Schmidt-Ullrich, RK .
CLINICAL CANCER RESEARCH, 2004, 10 (19) :6732-6743
[83]   EGFRvIII-mediated radioresistance through a strong cytoprotective response [J].
Lammering, G ;
Hewit, TH ;
Valerie, K ;
Contessa, JN ;
Amorino, GP ;
Dent, P ;
Schmidt-Ullrich, RK .
ONCOGENE, 2003, 22 (36) :5545-5553
[84]   Genetic instabilities in human cancers [J].
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1998, 396 (6712) :643-649
[85]   The response of autologous T cells to a human melanoma is dominated by mutated neoantigens [J].
Lennerz, V ;
Fatho, M ;
Gentilini, C ;
Frye, RA ;
Lifke, A ;
Ferel, D ;
Wölfel, C ;
Huber, C ;
Wölfel, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (44) :16013-16018
[86]   Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin [J].
Li, B ;
Yuan, M ;
Kim, IA ;
Chang, CM ;
Bernhard, EJ ;
Shu, HKG .
ONCOGENE, 2004, 23 (26) :4594-4602
[87]   AMPLIFICATION, ENHANCED EXPRESSION AND POSSIBLE REARRANGEMENT OF EGF RECEPTOR GENE IN PRIMARY HUMAN-BRAIN TUMORS OF GLIAL ORIGIN [J].
LIBERMANN, TA ;
NUSBAUM, HR ;
RAZON, N ;
KRIS, R ;
LAX, I ;
SOREQ, H ;
WHITTLE, N ;
WATERFIELD, MD ;
ULLRICH, A ;
SCHLESSINGER, J .
NATURE, 1985, 313 (5998) :144-147
[88]   T-CELLS SPECIFIC FOR THE MYELIN OLIGODENDROCYTE GLYCOPROTEIN MEDIATE AN UNUSUAL AUTOIMMUNE INFLAMMATORY RESPONSE IN THE CENTRAL-NERVOUS-SYSTEM [J].
LININGTON, C ;
BERGER, T ;
PERRY, L ;
WEERTH, S ;
HINZESELCH, D ;
ZHANG, YP ;
LU, HC ;
LASSMANN, H ;
WEKERLE, H .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (06) :1364-1372
[89]  
Loeb LA, 2001, CANCER RES, V61, P3230
[90]  
Lorimer IAJ, 1995, CLIN CANCER RES, V1, P859